Regeneron Pharmaceuticals, Inc. $REGN is Mcdonald Capital Investors Inc. CA’s 7th Largest Position

Mcdonald Capital Investors Inc. CA grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 218,045 shares of the biopharmaceutical company’s stock after buying an additional 21,272 shares during the period. Regeneron Pharmaceuticals accounts for 7.2% of Mcdonald Capital Investors Inc. CA’s holdings, making the stock its 7th biggest position. Mcdonald Capital Investors Inc. CA’s holdings in Regeneron Pharmaceuticals were worth $114,474,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. Brighton Jones LLC raised its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 41.8% in the first quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company’s stock worth $816,000 after buying an additional 379 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $1,246,000. Spire Wealth Management raised its holdings in shares of Regeneron Pharmaceuticals by 13.9% in the first quarter. Spire Wealth Management now owns 180 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 22 shares during the last quarter. Finally, Golden State Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 265.4% in the first quarter. Golden State Wealth Management LLC now owns 95 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several recent research reports. Jefferies Financial Group raised their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a report on Monday, August 4th. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Finally, Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $802.35.

Regeneron Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ REGN opened at $577.95 on Friday. The company’s 50-day simple moving average is $576.32 and its 200-day simple moving average is $562.62. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $943.83. The firm has a market cap of $61.26 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business earned $11.56 earnings per share. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.